RxDoctor Payments Data

Nitin Damle, MD

Internal Medicine · Wakefield, RINPI 1457399388

Payments from drug & device makers

$4,090in general payments, 2019–2025

Across 189 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$582
  • AstraZeneca$460
  • AbbVie$448
  • Pfizer$400
  • Lilly USA, LLC$349
  • GSK$348
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$2256%
  • Food & beverage$3,85994%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,090 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$213,896
Medicare patients
914
Services billed
3,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin159$167,207
EliquisApixaban172$138,041
RybelsusSemaglutide46$72,679
TrulicityDulaglutide47$55,513
XareltoRivaroxaban45$48,440
OzempicSemaglutide38$46,506
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$25,940
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$23,553
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$15,842
Atorvastatin Calcium1,095$11,777
Tresiba Flextouch U-200Insulin Degludec13$9,404
Breo ElliptaFluticasone/Vilanterol22$8,490
Losartan Potassium659$6,786
Levothyroxine Sodium494$6,466
Omeprazole386$5,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$176$167,207159 claims
PfizerEliquis$400$138,041172 claims
Novo NordiskRybelsus, Ozempic$582$119,18684 claims
Lilly USA, LLCTrulicity$349$55,51347 claims
GSKTrelegy Ellipta, Breo Ellipta$348$34,43044 claims
AbbVieSynthroid$448$4,63668 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Wakefield

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →